-
公开(公告)号：EP2467383A1
公开(公告)日：2012-06-27
申请号：EP10762878.6
申请日：2010-08-18
申请人： Novartis AG
发明人： DAI, Miao , FU, Xingnian , HE, Feng , JIANG, Lei , LI, Yue , LIANG, Fang , LIU, Lei , MI, Yuan , XU, Yao-chang , XUN, Guoliang , YAN, Xiaoxia , YU, Zhengtian , ZHANG, Ji, Yue
IPC分类号： C07D471/04 , A61K31/52 , A61P35/00
CPC分类号： C07D471/04
摘要： The invention relates to compounds of formula (I) and salts thereof wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).
-
2.发明公开HETEROCYCLIC HYDRAZONE COMPOUNDS AND THEIR USES TO TREAT CANCER AND INFLAMMATION 审中-公开杂环腙及其用途是治疗癌症和炎症的治疗
公开(公告)号：EP2464649A1
公开(公告)日：2012-06-20
申请号：EP10744553.8
申请日：2010-08-10
申请人： Novartis AG
发明人： FU, Xingnian , HE, Feng , LI, Yue , LIU, Lei , MI, Yuan , XU, Yao-chang , XUN, Guoliang , YU, Zhengtian , ZHANG, Ji Yue (Jeff) , DAI, Miao
IPC分类号： C07D487/04 , A61K31/4985 , A61P35/00 , A61P29/00
CPC分类号： C07D487/04
摘要： The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).
-
公开(公告)号：EP4219689A3
公开(公告)日：2023-12-20
申请号：EP23152887.8
申请日：2016-12-30
发明人： MOTZ, Gregory , MAVRAKIS, Konstantinos John , LIU, Jinbiao , LIU, Lei , ZHENG, Qiangang , XUN, Guoliang , XIAO, Qitao
IPC分类号： C12N5/0783 , C12N15/113 , C07D295/00 , C07D401/14 , A61K35/17 , C07D207/34 , C07K16/24 , C07K16/28 , C07K16/30 , A61P35/00
摘要： The present invention relates generally to the use of LSD1 inhibitors in connection with use and manufacture of immune effector cells (e.g., T cells, NK cells), e.g., engineered to express a chimeric antigen receptor (CAR), to treat a subject having a disease, e.g., a disease associated with expression of a tumor antigen.
-
公开(公告)号：EP3523290A1
公开(公告)日：2019-08-14
申请号：EP17854999.4
申请日：2017-09-29
发明人： MOTZ, Gregory , MAVRAKIAS, Konstantinos John , LIU, Jinbiao , LIU, Lei , ZHENG, Qiangang , XUN, Guoliang , XIAO, Qitao
IPC分类号： C07D401/04 , C07D209/14 , A61K31/33 , A61P35/00
-
公开(公告)号：EP4219689A2
公开(公告)日：2023-08-02
申请号：EP23152887.8
申请日：2016-12-30
发明人： MOTZ, Gregory , MAVRAKIAS, Konstantinos John , LIU, Jinbiao , LIU, Lei , ZHENG, Qiangang , XUN, Guoliang , XIAO, Qitao
IPC分类号： C12N5/0783 , C12N15/113 , C07D295/00 , C07D401/14 , A61K35/17 , C07D207/34 , C07K16/24 , C07K16/28 , C07K16/30 , A61P35/00
摘要： The present invention relates generally to the use of LSD1 inhibitors in connection with use and manufacture of immune effector cells (e.g., T cells, NK cells), e.g., engineered to express a chimeric antigen receptor (CAR), to treat a subject having a disease, e.g., a disease associated with expression of a tumor antigen.
-
-
-
-
搜索结果
5 条记录 (耗时 0.017 秒)
